PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
J Pediatr. Author manuscript; available in PMC 2012 March 1.
Published in final edited form as:
PMCID: PMC3062091
NIHMSID: NIHMS253666

Increase in Invasive Streptococcus pneumoniae Infections in Children with Sickle Cell Disease since Pneumococcal Conjugate Vaccine Licensure

Timothy L. McCavit, M.D.,1,3 Charles T. Quinn, M.D., M.S.,1,3 Chonnamet Techasaensiri, M.D.,2,3 and Zora R. Rogers, M.D.1,3

Abstract

Invasive pneumococcal disease (IPD) in children with sickle cell disease (SCD) has decreased with prophylactic penicillin, pneumococcal polysaccharide vaccine, and pneumococcal protein-conjugate vaccine (PCV7) usage. We report 10 IPD cases since PCV7 licensure, including a recent surge of non-vaccine serotypes. IPD continues to be a serious risk in SCD.

Keywords: sickle cell disease, Streptococcus pneumoniae, serotype, infection

The natural history of sickle cell disease (SCD) includes a marked susceptibility to infection by Streptococcus pneumoniae. Prior to the advent of the polyvalent polysaccharide S. pneumoniae vaccine (PPV23), invasive pneumococcal disease (IPD) affected approximately 10% of children with SCD by age 51, an infection risk that was 300 times greater than the general population.2 This susceptibility is primarily attributable to functional asplenia.3 By 1990, PPV234 and penicillin prophylaxis5 reduced the burden of IPD in SCD. More recently, a further 90%6 and 68%7 reduction of IPD in SCD was reported following the introduction of the heptavalent pneumococcal protein-conjugate vaccine (PCV7) in 2000.

However, a recent increase of IPD in hematologically normal children with non-vaccine serotypes has been reported.8 Reports of the trend in pneumococcal serotypes in patients with SCD because PCV7 licensure are limited.6, 7 We sought to describe cases of IPD in patients with SCD since PCV7 licensure.

Cases

We identified all cases of IPD at Children’s Medical Center Dallas after 2/17/2000 (PCV7 licensure) from administrative records. Cases had at least one ICD-9CM code for SCD (282.6x, 282.41, 282.42) and at least one IPD code (038.2, 041.2, 320.1, 481, 567.1). To ensure complete case identification, we also cross-referenced our sickle cell database for IPD. Sixteen cases were identified; 6 were excluded (2 for erroneous ICD-9CM coding, 2 for incomplete medical records, and 2 for unavailability of the pneumococcal isolate at an outside center). Pneumococcal isolates were serotyped using the capsular swelling method with commercially available rabbit anti-pneumococcal antisera (Statens Serum Institut, Copenhagen, Denmark.) The Institutional Review Board of the University of Texas Southwestern Medical Center approved this study.

Details of the 10 cases are presented in the Table. Patients were predominantly under the age of 5 years with sickle cell anemia (SS). Consistent with our center’s routine practice, all cases under age 5 with SS or sickle β0 thalassemia (Sβ0) had been prescribed prophylactic penicillin. Adherence to penicillin was not formally assessed. Additionally, we routinely administer PPV23 at age 2 and 5 years and ensure completion of the PCV7 series by age 18 months for all genotypes. The cases’ pneumococcal vaccine status is presented in the Table.

Table
Characteristics of IPD in Children with SCD

Available isolates were predominantly non-vaccine (PCV7 and PPV23) serotype: 3 were 23A and 1 each was 6A, 7B/C, 15A/C/F, and 23B. The two isolates with vaccine (PPV23) serotype were 19A and occurred in unvaccinated patients. The mean presenting white blood cell (WBC) count was above baseline (22,000/mm3 vs 13,600/mm3), and the mean hemoglobin concentration (6.9 vs 7.5 g/dL) and percentage of reticulocytes (7.6 vs 10.8%) were below baseline. Baseline values were calculated as the average of 3 preceding steady-state values. IPD caused significant morbidity: 5 patients were admitted to the intensive care unit, 4 had respiratory failure, 4 had acute renal failure, 2 had acute stroke, and 2 had meningitis.

One child died (case 7), a 6 year old girl with sickle hemoglobin-C disease. She was brought to the emergency department (ED) with 1-week of cough and congestion, one day of vomiting, and several hours of fever to 104°F. Upon presentation, she was awake, alert and in no distress without focal findings of infection. The initial complete blood count (CBC) showed a WBC count of 9,100/mm3 and hemoglobin of 9.9 g/dL and platelets of 243 000/mm3. Three hours later, following intravenous antibiotic therapy and while still in the ED, she became unresponsive, developed massive hepatic enlargement, and quickly progressed to cardiorespiratory failure. Repeat CBC showed a WBC count of 21,700/mm3 hemoglobin of 3.7 g/dL, and platelets of 33 000/mm3. Resuscitation including cannulation for extra-corporeal membrane oxygenation (ECMO) was ineffective and she died 12 hours after presentation. Blood culture grew S. pneumoniae within 8 hours. Final clinicopathologic diagnosis was septic shock complicated by acute hepatic sequestration.

The Figure shows the crude annual frequency of IPD at our center between 1980 and 2009. The number of patients actively followed at our center during this time-frame remained relatively stable (approximately 650 per year). Pre-PCV7 infections were identified by query of our clinical database; no isolates were available for study. The crude frequency of IPD at our center fell to zero shortly after licensure of PCV7 (2001–2003), but there appears to be a recent increase in IPD that began in 2004.

Figure 1
Temporal changes in IPD related to PCV7 licensure

Discussion

We report 10 cases of IPD in children with SCD in our institution since PCV7 licensure in 2000. These cases are informative and potentially alarming in several respects. First is the apparent recent increase in IPD cases. Two other reports describe IPD in SCD since PCV7 licensure, but included relatively short follow-up periods after licensure (2 and 4 years).6, 7 Similar to these reports, we encountered few cases of IPD immediately after PCV7 licensure. With longer follow-up since PCV7 licensure (9 years), however, we now observe an increasing frequency of IPD, especially in the past 2 years. Further study of IPD in patients with SCD is needed to determine if our experience is occurring in other SCD populations.

Second, our IPD cases were predominantly with serotypes not contained in PCV7 or PPV23. This finding is consistent with the 89.1% prevalence of non-vaccine serotypes in 393 pneumococcal isolates in children without SCD in 2005-2006.9 A new pneumococcal conjugate vaccine, PCV13, was recently FDA-approved and will add serotypes 1, 3, 5, 6A, 7F, and 19A to those in PCV7.10 However, this additional coverage of PCV-13 would have protected only 3 of our 9 serotyped cases.

Third, the morbidity and mortality in our cases is remarkable. The case fatality rate of IPD was less than 1% in unselected children in the United Kingdom11 but was 10% in patients with SCD in the mid-1990s.12 Few studies have detailed morbidity related to IPD, yet our cases frequently had sepsis and respiratory failure requiring intensive care; some had renal failure or stroke. Consistent with prior reports, our older patients seem to have a higher morbidity associated with IPD.12, 13

In summary, we have seen a recent increase in the frequency of IPD which is caused by non-vaccine serotypes. IPD continues as a serious and sometimes fatal complication of SCD. These findings should drive continued efforts to develop better vaccines, improve the early identification and follow-up of patients with SCD by newborn screening, encourage adherence to penicillin prophylaxis and pneumococcal vaccination, and educate patients with SCD, families, and providers regarding the importance of promptly seeking medical attention for high fever.

Acknowledgments

Supported by NIH/NHLBI (U54 HL0705088-06) and NIH (UL1 RR024982-03).

We would like to thank Dr. George R. Buchanan for his thoughtful reviews of the manuscript.

Footnotes

The authors declare no conflicts of interest.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

References

1. Powars DR. Natural history of sickle cell disease--the first ten years. Semin Hematol. 1975;12:267–85. [PubMed]
2. Barrett-Connor E. Bacterial infection and sickle cell anemia. An analysis of 250 infections in 166 patients and a review of the literature. Medicine (Baltimore) 1971;50:97–112. [PubMed]
3. Pearson HA, Spencer RP, Cornelius EA. Functional asplenia in sickle-cell anemia. N Engl J Med. 1969;281:923–6. [PubMed]
4. Ammann AJ, Addiego J, Wara DW, Lubin B, Smith WB, Mentzer WC. Polyvalent pneumococcal-polysaccharide immunization of patients with sickle-cell anemia and patients with splenectomy. N Engl J Med. 1977;297:897–900. [PubMed]
5. Gaston MH, Verter JI, Woods G, Pegelow C, Kelleher J, Presbury G, et al. Prophylaxis with oral penicillin in children with sickle cell anemia. A randomized trial. N Engl J Med. 1986;314:1593–9. [PubMed]
6. Halasa NB, Shankar SM, Talbot TR, Arbogast PG, Mitchel EF, Wang WC, et al. Incidence of invasive pneumococcal disease among individuals with sickle cell disease before and after the introduction of the pneumococcal conjugate vaccine. Clin Infect Dis. 2007;44:1428–33. [PubMed]
7. Adamkiewicz TV, Silk BJ, Howgate J, Baughman W, Strayhorn G, Sullivan K, et al. Effectiveness of the 7-valent pneumococcal conjugate vaccine in children with sickle cell disease in the first decade of life. Pediatrics. 2008;121:562–9. [PubMed]
8. Kaplan SL, Barson WJ, Lin PL, Stovall SH, Bradley JS, Tan TQ, et al. Serotype 19A Is the most common serotype causing invasive pneumococcal infections in children. Pediatrics. 125:429–36. [PubMed]
9. Critchley IA, Jacobs MR, Brown SD, Traczewski MM, Tillotson GS, Janjic N. Prevalence of serotype 19A Streptococcus pneumoniae among isolates from U.S. children in 2005–2006 and activity of faropenem. Antimicrob Agents Chemother. 2008;52:2639–43. [PMC free article] [PubMed]
10. Scott DA, Komjathy SF, Hu BT, Baker S, Supan LA, Monahan CA, et al. Phase 1 trial of a 13-valent pneumococcal conjugate vaccine in healthy adults. Vaccine. 2007;25:6164–6. [PubMed]
11. Shackley F, Knox K, Morris JB, Crook D, Griffiths D, Mayon-White R, et al. Outcome of invasive pneumococcal disease: a UK based study. Oxford Pneumococcal Surveillance Group. Arch Dis Child. 2000;83:231–3. [PMC free article] [PubMed]
12. Hord J, Byrd R, Stowe L, Windsor B, Smith-Whitley K. Streptococcus pneumoniae sepsis and meningitis during the penicillin prophylaxis era in children with sickle cell disease. J Pediatr Hematol Oncol. 2002;24:470–2. [PubMed]
13. Olopoenia L, Frederick W, Greaves W, Adams R, Addo FE, Castro O. Pneumococcal sepsis and meningitis in adults with sickle cell disease. South Med J. 1990;83:1002–4. [PubMed]